| Title: |
Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis |
| Authors: |
Yarmolinsky, J; Bouras, E; Constantinescu, A; Burrows, K; Bull, CJ; Vincent, EE; Martin, RM; Dimopoulou, O; Lewis, SJ; Moreno, V; Vujkovic, M; Chang, KM; Voight, BF; Tsao, PS; Gunter, MJ; Hampe, J; Pellatt, AJ; Pharoah, PDP; Schoen, RE; Gallinger, S; Jenkins, MA; Pai, RK; Eeles, RA; Haiman, CA; Kote-Jarai, Z; Schumacher, FR; Benlloch, S; Al Olama, AA; Muir, K; Berndt, SI; Conti, DV; Wiklund, F; Chanock, S; Wang, Y; Stevens, VL; Tangen, CM; Batra, J; Clements, JA; Grönberg, H; Pashayan, N; Schleutker, J; Albanes, D; Weinstein, S; Wolk, A; West, CML; Mucci, LA; Cancel-Tassin, G; Koutros, S; Sørensen, KD; Grindedal, EM; Neal, DE; Hamdy, FC; Donovan, JL; Travis, RC; Hamilton, RJ; Ingles, SA; Rosenstein, BS; Lu, YJ; Giles, GG; Kibel, AS; Vega, A; Kogevinas, M; Penney, KL; Park, JY; Stanford, JL; Cybulski, C; Nordestgaard, BG; Nielsen, SF; Brenner, H; Maier, C; Kim, J; John, EM; Teixeira, MR; Neuhausen, SL; De Ruyck, K; Razack, A; Newcomb, LF; Lessel, D; Kaneva, R; Usmani, N; Claessens, F; Townsend, PA; Castelao, JE; Roobol, MJ; Menegaux, F; Khaw, KT; Cannon-Albright, L; Pandha, H; Thibodeau, SN; Hunter, DJ; Kraft, P; Blot, WJ; Riboli, E; Gill, D; Tsilidis, KK |
| Publisher Information: |
Springer Science and Business Media LLC |
| Publication Year: |
2023 |
| Collection: |
The University of Melbourne: Digital Repository |
| Description: |
AIMS/HYPOTHESIS: Epidemiological studies have generated conflicting findings on the relationship between glucose-lowering medication use and cancer risk. Naturally occurring variation in genes encoding glucose-lowering drug targets can be used to investigate the effect of their pharmacological perturbation on cancer risk. METHODS: We developed genetic instruments for three glucose-lowering drug targets (peroxisome proliferator activated receptor γ [PPARG]; sulfonylurea receptor 1 [ATP binding cassette subfamily C member 8 (ABCC8)]; glucagon-like peptide 1 receptor [GLP1R]) using summary genetic association data from a genome-wide association study of type 2 diabetes in 148,726 cases and 965,732 controls in the Million Veteran Program. Genetic instruments were constructed using cis-acting genome-wide significant (p |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| ISSN: |
0012-186X |
| Relation: |
https://hdl.handle.net/11343/345404 |
| Availability: |
https://hdl.handle.net/11343/345404 |
| Rights: |
https://creativecommons.org/licenses/by/4.0 ; CC BY |
| Accession Number: |
edsbas.6706EEDB |
| Database: |
BASE |